Last reviewed · How we verify
Azithromycin Ophthalmic Solution
At a glance
| Generic name | Azithromycin Ophthalmic Solution |
|---|---|
| Sponsor | Ehab Mohamed Elsayed Mohamed Saad |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction (PHASE4)
- Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye (PHASE1, PHASE2)
- Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis (PHASE3)
- Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis (NA)
- Tear Concentrations and Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers (PHASE1)
- Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers (PHASE1)
- PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients (PHASE2)
- Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin Ophthalmic Solution CI brief — competitive landscape report
- Azithromycin Ophthalmic Solution updates RSS · CI watch RSS
- Ehab Mohamed Elsayed Mohamed Saad portfolio CI